Interleukin 2 (IL2) Soluble Receptor Alpha
The interleukin-2 receptor is composed of three subunits, interleukin-2 receptor alpha (IL-2Ra), interleukin-2 receptor beta (IL-2Rb), and interleukin-2 receptor gamma (IL-2Rγ). Interleukin 2 receptor alpha (IL-2Rα), also known as CD25 or the Tac antigen, is a type 1 transmembrane glycoprotein found on the cytoplasm side of the membrane. Normal levels of IL-2Ra are seen in patients with healthy immune systems. IL2Rα is present on activated T cells, but is also found in serum in a soluble form when increased. Increased levels of the soluble IL-2Rα in serum correlate with activation of T and/or B cells and the activation of the immune system as seen in many autoimmune disorders such as transplant rejection, Lupus Erythematosus (SLE), and rheumatoid arthritis (RA). IL-2Rα is also increased in some leukemias and lymphomas due to the presence of IL-2Ra expression on Natural Killer Cells (NK cells) and lymphoma cells. IL-2Rα levels can also be useful in the prognosis in non-Hodgkin lymphoma patients. Monitoring the disease activity of HIV patients is easily correlated with the presence of IL-2Ra in the serum because of the increased amounts seen in immune system activation. Increased amounts of IL-2Ra levels over time can create an imbalance in immune system activation and create a susceptibility to many types of infections. Decreased amounts of IL-2Ra are seen in activated T-cell deficiencies, in loss from apoptosis, polycystic kidney disease (PKD), some cancers, and in IL-2 deficiencies.
- As an aid in prognosis and management of patients with leukemia or lymphoma
- Monitor therapy in lymphoma/leukemia patients
- Monitor therapy in HIV patients
- Monitor patients post transplant for rejection
- Aid in diagnosis of some autoimmune disorders
Increased in:
- T- or B-cell Lymphomas
- Hairy cell leukemia
- Lupus Erythematosus
- Rheumatoid arthritis
- HIV
- Non-Hodgkin lymphoma
- Infection
- Inflammation
- Some other autoimmune diseases
- Trauma
Decreased in:
- Activated T-cell deficiency
- Apoptosis
- Polycystic Kidney Disease (PKD)
- IL-2 deficiency
0-1033 pg/mL
Electrochemiluminescence immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA), LC/MS.
Serum (SST) or Plasma EDTA (Lavender),Heparin (Green).
Separate serum or Plasma and keep frozen.
Stability
- Ambient: 24 hours
- Refrigerated: Unacceptable
- Frozen: 30 days
1-2 weeks.
- Ann Intern Med. 1990; 113(8):619-27 (review). [PMID: 2205142]
- Acta Medica (Hradec Kralove). 1996; 39(1):3-6 (review). [PMID: 9106384]
- Cancer Cells. 1991; 3(12):471-9. [PMID: 1820093]
- Annu Rev Cell Biol. 1989;5:397-425 (review). [PMID: 2688708]
- Eur J Cancer. 1995; 31A(3):401-8 (review). [PMID: 7540404]
- Adv Immunol. 1998;70:1-81 (review). [PMID: 9755337]